Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone310-358-3200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.67 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date8/8/2019 (Estimated)
OptionableNot Optionable
Capricor Therapeutics (NASDAQ:CAPR) Frequently Asked Questions
What is Capricor Therapeutics' stock symbol?
Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."
How were Capricor Therapeutics' earnings last quarter?
Capricor Therapeutics Inc (NASDAQ:CAPR) released its earnings results on Monday, May, 13th. The biotechnology company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.03. The biotechnology company earned $0.23 million during the quarter, compared to analysts' expectations of $0.40 million. Capricor Therapeutics had a negative return on equity of 225.30% and a negative net margin of 936.22%. View Capricor Therapeutics' Earnings History.
When is Capricor Therapeutics' next earnings date?
What price target have analysts set for CAPR?
2 brokerages have issued 12 month target prices for Capricor Therapeutics' stock. Their predictions range from $4.00 to $4.00. On average, they expect Capricor Therapeutics' stock price to reach $4.00 in the next year. This suggests a possible upside of 1,076.5% from the stock's current price. View Analyst Price Targets for Capricor Therapeutics.
What is the consensus analysts' recommendation for Capricor Therapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Capricor Therapeutics.
What are Wall Street analysts saying about Capricor Therapeutics stock?
Here are some recent quotes from research analysts about Capricor Therapeutics stock:
- 1. According to Zacks Investment Research, "Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. " (5/3/2019)
- 2. HC Wainwright analysts commented, "Valuation and potential impediments to achieving it. We maintain our Buy rating and our price target of $3.50. Our price target is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, CAP-1002 in DMD patients. We believe this method is appropriate in capturing the value of the clinical stage pipeline by allowing us to flex multiple assumptions, including chance of success, peak sales estimates, and year of commercial launch." (5/1/2019)
- 3. Maxim Group analysts commented, "Capricor announced it has resumed dosing in the HOPE-2 trial, which is testing CAP-1002 for already enrolled patients (n=20) with Duchenne muscular dystrophy (DMD)." (2/6/2019)
Has Capricor Therapeutics been receiving favorable news coverage?
Headlines about CAPR stock have been trending neutral on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Capricor Therapeutics earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days.
Are investors shorting Capricor Therapeutics?
Capricor Therapeutics saw a decline in short interest in April. As of April 15th, there was short interest totalling 288,975 shares, a decline of 47.6% from the March 29th total of 551,983 shares. Based on an average daily trading volume, of 397,721 shares, the short-interest ratio is currently 0.7 days. Currently, 1.4% of the company's shares are sold short. View Capricor Therapeutics' Current Options Chain.
Who are some of Capricor Therapeutics' key competitors?
Some companies that are related to Capricor Therapeutics include Clearside Biomedical (CLSD), Teligent (TLGT), Bio-Path (BPTH), Celsion (CLSN), Lipocine (LPCN), KemPharm (KMPH), VIVUS (VVUS), Aerpio Pharmaceuticals (ARPO), BIOLINERX LTD/S (BLRX), Akari Therapeutics (AKTX), Sienna Biopharmaceuticals (SNNA), Generex Biotechnology (GNBT), ContraFect (CFRX), Aptevo Therapeutics (APVO) and Oncomed Pharmaceuticals (OMED).
What other stocks do shareholders of Capricor Therapeutics own?
Who are Capricor Therapeutics' key executives?
Capricor Therapeutics' management team includes the folowing people:
- Frank I. Litvack M.D., Independent Executive Chairman of the Board (Age 59)
- Linda Marban Ph.D., President, Chief Executive Officer, Director (Age 51)
- Anthony Bergmann, Chief Financial Officer, Principal Accounting Officer (Age 32)
- Karen G. Krasney J.D., Executive Vice President, General Counsel (Age 62)
- Thomas Lyle Copmann Ph.D., Vice President - Regulatory Affairs and Drug Development (Age 61)
- Houman Hemmati M.D., Ph.D., Vice President - Medical & Clinical Development, New Therapies
- Luis Rodriguez-Borlado Ph.D., Vice President - Regenerative Therapies
- Rachel Smith Ph.D., Vice President - Research & Development (Age 36)
- Deborah Ascheim M.D., Chief Medical Officer
- Joshua A. Kazam, Director (Age 40)
Who are Capricor Therapeutics' major shareholders?
Which major investors are buying Capricor Therapeutics stock?
How do I buy shares of Capricor Therapeutics?
Shares of CAPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Capricor Therapeutics' stock price today?
One share of CAPR stock can currently be purchased for approximately $0.34.
How big of a company is Capricor Therapeutics?
Capricor Therapeutics has a market capitalization of $11.79 million and generates $1.67 million in revenue each year. The biotechnology company earns $-15,190,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis.
What is Capricor Therapeutics' official website?
How can I contact Capricor Therapeutics?
Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The biotechnology company can be reached via phone at 310-358-3200 or via email at [email protected]
MarketBeat Community Rating for Capricor Therapeutics (NASDAQ CAPR)
MarketBeat's community ratings are surveys of what our community members think about Capricor Therapeutics and other stocks. Vote "Outperform" if you believe CAPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CAPR will underperform the S&P 500 over the long term. You may vote once every thirty days.
